Objective To analysis The clinical efficacy of XiaoErKang granule combined with MAMIAI to 98 children with autumn ped-iatric diarrhea.Methods98 children with diarrhea from January 2015 to December 2015 were divided into 49 cases with treatment group and 49 cases with the control group.The control group received MAMIAI,and the treatment group received XiaoErKang granule combined with MAMIAI,following-up and recording related signs disappearing time,changes of serum factors and the clinical results.Results①The fever subsided, stop vomiting and stool recovery time of treatment group were (18.24±2.13h,1.59±0.51d,3.67±0.51d),shortter than the control group with (27.05±3.09h,2.72±0.64d,5.69±0.86d),and the differences were statistically significant (P<0.05).②The hs-CRP and TNF-ɑ levels of treatment group were (4.58±0.61ng/L,8.14±0.79pg/mL),lowwer than the control group with (8.13±0.75ng/L,11.49±1.87pg/mL),and the differences were statistically significant (P<0.05).③The IL-1 and IL-6 levels of treatment group were(27.49±3.16,9.73±1.25)pg/mL,lowwer than the control group with (40.16±5.72,12.65±1.77)pg/mL,and the differences were statistically significant (P<0.05).④The treatment effect of treatment group were 91.84%,better than the control group with 73.47%,and the differences were statistically significant (P<0.05).ConclusionThe effece of XiaoErKang granule joint MAMIAI to children with diarrhea can reduce levels of inflammation,and it is effective.

Objective To assess the effect and safety of epalrestat on diabetic peripheral neuropathy ( DPN) . Methods Retrieved from PubMed,Cochrane Library,CNKI,VIP,CBM and Wanfang database ,RCTs about epalrestat in the treatment of DPN were included from establishment to July 2017 and comprehensively evaluated .Two reviewers independently screened literature according to the inclusion and exclusion criteria , extracted data , assessed the risk bias of included studies , and then analysis was performed using the RevMan 5.3 software.Results A total of 14 RCTs involved 1945 patients were included .The results of systematic review and Meta -analysis showed that epalrestat could significantly improve DPN compared with the placebo /blank control group ( OR =8.01,95％CI:4.48-14.32,P<0.01;OR=2.49,95％CI:1.71-3.65,P<0.01).Compared with the placebo group and the blank control group,epalrestat could significantly improve the median sensory nerve conduction velocity ( OR=3.92,95％Cl:1.37-6.47,P<0.01),peroneal nerve conduction velocity (OR=4.87,95％CI:2.35-7.39,P<0.01) and ulnar nerve conduction velocity ( OR =4.58, 95％CI:2.54-6.63, P <0.01 ).The major adverse reactions were gastrointestinal reactions ,nausea and vomiting ,but no serious adverse reactions were observed in the epalrestat group , compared with the placebo/blank control group,the difference was statistically significant (OR =12.87,95％CI:2.35-70.50,P<0.01).Conclusion Epalrestat can effectively treat DPN through improving the body's sensory nerve conduction velocity,and it has no serious adverse reactions .Since the limitation of quality and quantity of included studies,large-scale and high-quality randomized double -blinding controlled trails are needed to verify the above conclusion.

Conventional transcatheter aortic valve replacement is normally recommended with transthoracic echocardiography, and contrast agent mediated fluoroscopy under anesthesia to guide a better implantation of the transcatheter valve. However, iodine-containing contrast agent possibly damages the patient’s kidney, and even induces the acute kidney injury. We reported a 75-year-old patient diagnosed with severe aortic valve stenosis, moderate regurgitation, and chronic renal failure. We performed the aortic valve replacement under the guidance of fluoroscopy and transesophageal ultrasound without contrast agent. Seven days after surgery, the patient recovered well and discharged with alleviated aortic stenosis and fixed transcatheter aortic valve.